Trametinib (Trm) is a highly selective allosteric MEK inhibitor (MEKi) that potently and persistently inhibits ERK1/2 activation.(1) In 2013, Trm received FDA clearance for treatment of BRAF V600E/K-mutant melanoma, becoming the first MEKi approved for any indication. Here, BRAF is linked to melanoma.